Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifitegrast - Novartis

Next Previous
X
Search
Drug Profile

Lifitegrast - Novartis

Alternative Names: Lifitegrast; OJL-332; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer Novartis; SARcode Bioscience; Shire
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Benzofurans; Eye disorder therapies; Isoquinolines; Propionic acids; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 18 Jun 2024 9419949- deal updated
  • 02 Feb 2024 Valeo Pharma and Novartis Pharmaceuticals amended the agreement for commercialisation of Lifitegrast
  • 29 Sep 2023 Bausch and Lomb acquires lifitegrast from Novartis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top